Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Kayali, F. [1 ]
Janjua, M. A. [1 ]
Laber, D. A. [1 ]
Miller, D. M. [1 ]
Day, J. M. [1 ]
Kloecker, G. H. [1 ]
机构：
[1] Univ Louisville, Louisville, KY 40292 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19077
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CLINICAL BENEFITS OF SEQUENTIAL ADMINISTRATION OF DOCETAXEL AND INTERMITTENT ERLOTINIB AS A SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC), A PHASE II RANDOMIZED STUDY
    Juan, O.
    Aparisi Aparisi, F. D. A.
    Sanchez, A.
    Giner Marco, V.
    Munoz Langa, J.
    Esquerdo, G.
    Lopez, A.
    Garde, J.
    Garcia Sanchez, J.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S61 - S61
  • [22] Clinical benefits of sequential administration of docetaxel and intermittent erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC): A phase II randomized study
    Aparisi, Francisco
    Sanchez-Hernandez, Alfredo
    Giner, Vicente
    Munoz-Langa, Jose
    Esquerdo, Gaspar
    Lopez Jimenez, Antonio
    Garde, Javier
    Garcia Sanchez, Jose
    Juan Vidal, Oscar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] CLINICAL BENEFITS OF SEQUENTIAL ADMINISTRATION OF DOCETAXEL AND INTERMITTENT ERLOTINIB AS A SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC), A PHASE II RANDOMIZED STUDY
    Juan Vidal, Oscar
    Garcia Sanchez, Jose
    Sanchez, Alfredo
    Giner, Vicente
    Munoz Langa, Jose
    Esquerdo, Gaspar
    Lopez, Antonio
    Garde, Javier
    de Asis Aparisi, Francisco
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1177 - S1178
  • [24] Gemcitabine Plus Vinorelbine as Second-line Chemotherapy of the Patients of Previously Treated Non-small Cell lung Cancer: Phase II Trial
    Jang, Pil Soon
    Kang, Hyun Mo
    Lee, Jeong Eun
    Kwon, Seon Jung
    An, Jin Young
    Lee, Yun Sun
    Jeong, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (04) : 344 - 351
  • [25] Second-line erlotinib for non-small-cell lung cancer Reply
    Ciuleanu, Tudor
    LANCET ONCOLOGY, 2012, 13 (04): : E142 - E142
  • [26] A multicenter, open, randomized, phase II study to investigate the sequential administration of docetaxel and intermittent erlotinib versus erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC)
    Aparisi, F.
    Garcia Sanchez, J.
    Sanchez-Hernandez, A.
    Giner, V.
    Munoz-Langa, J.
    Esquerdo, G.
    Lopez Jimenez, A.
    Garde, J.
    Juan Vidal, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Second-line chemotherapy for non-small cell lung cancer
    De Marinis, F.
    De Santis, S.
    De Petris, L.
    ANNALS OF ONCOLOGY, 2006, 17 : V68 - V71
  • [28] Non-small cell lung cancer: second-line and beyond
    Stahel, R. A.
    ANNALS OF ONCOLOGY, 2006, 17 : X97 - X100
  • [29] Second-line chemotherapy for non-small cell lung cancer
    Ruckdeschel, JC
    CHEST, 2006, 129 (04) : 840 - 842
  • [30] A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
    Sculier, JP
    Lafitte, JJ
    Berghmans, T
    Thiriaux, J
    Lecomte, J
    Efremidis, A
    Ninane, V
    Paesmans, M
    Mommen, P
    Klastersky, J
    LUNG CANCER, 2000, 29 (01) : 67 - 73
12345